Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies. The company was founded around record-breaking integrase technology for improving gene editing vectors.
2 investors
Koniku develops co-processors built from biological neurons, using DNA sequences to create receptors that enable sensing applications. Its uses include detecting threats for airport security, drones for identifying buried IEDs, and taste-sensitive devices for quality assurance.
2 investors
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's. Its approach uses antibody engineering to enable therapies with meaningful central nervous system exposure delivered subcutaneously.
2 investors
Kovina develops first-in-class small molecule antiviral drugs to treat HPV-induced cancers and premalignant infections such as cervical and anal dysplasia. The company aims to offer non-surgical treatment options for patients living with HPV.
2 investors
Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
2 investors
Kultevat develops biomanufacturing using its Kultevar dandelion (TKS) to produce Kultra natural rubber and other biomaterials as regenerative, plant-based alternatives to petrochemical polymers like synthetic rubber. It partners with brands and manufacturers seeking to replace extractive rubber sourcing in their supply chains with materials made through regenerative agriculture.
2 investors
Kupando is a biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. Its lead candidate KUP101 combines a TLR4 and a TLR7 agonist in a liposomal formulation for treating solid tumors and preventing infectious diseases.
2 investors
Kypha develops clinical diagnostic tests for immune system biomarkers, particularly complement activity markers, and provides solutions for real-time immune insights across therapeutic areas. The company serves biopharma firms, clinical laboratories, and medical institutions through a network of clinical collaborators and research partners.
2 investors
kyron.bio develops protein and antibody therapeutics using a glycan-engineering platform that controls glycosylation patterns. The company operates in the biotech sector and is based in Paris within the Paris Biotech Santé incubator.
2 investors
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
2 investors
L-Nutra develops fasting-mimicking technology and nutrition-based products designed to slow biological aging and treat age-related diseases. The company focuses on translating longevity research into consumer health interventions.
2 investors
LabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
2 investors
Lakeshore Biopharma (Nasdaq: LSB, formerly Yisheng Biopharma) is a biopharmaceutical company focused on developing, producing, and selling vaccines and immunological products for infectious diseases. Its main marketed product is a lyophilized human rabies vaccine (Vero cell), and it uses a proprietary PIKA immunomodulating technology.
2 investors
Lantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.
2 investors
Lassogen engineers lasso peptides — structurally unique 3D scaffolds — into therapeutics it calls Lassotides, designed to combine the strengths of antibodies and small molecules. The company develops these therapeutics to treat challenging diseases and disease targets inadequately addressed by existing approaches.
2 investors
Laza Medical develops an AI- and robotics-powered ultrasound imaging system for structural heart, electrophysiology, and diagnostic cardiac procedures, combining real-time 3D heart modeling, procedural guidance, and robotic probe control. The system is aimed at clinicians and hospital care teams to simplify image guidance, and is not yet approved for sale in any country.
2 investors
Lead Pharma develops small-molecule therapies targeting autoimmune disease, metabolic disease, and cancer. The company serves patients in need of innovative pharmaceutical treatments.
2 investors
LEAH Labs engineers gene-edited CAR-T cell therapies to treat cancer in pet dogs, with the goal of generating translational insights for human cancer therapy. The company uses proprietary gene editing and protein design to develop therapeutic treatments for companion animal oncology.
2 investors
Legend Biotech is a biotechnology company. The provided page content is an external-link disclaimer and contains no substantive information about the company's products or business.
2 investors
Lentitek develops an alternative lentiviral vector production platform based on novel synthetic promoter technology, aimed at improving quality and yield in CAR-T manufacture and enabling in-vivo and armoured CAR applications. It works with advanced therapy (ATMP) asset developers through a serviced CRO license model to integrate and validate its vector solution.
2 investors
Leon develops nanoparticle-based drug delivery systems for therapeutic applications in healthcare. The company leverages nanotechnology to improve drug efficacy and patient outcomes.
2 investors
Lepidext develops a biocontrol product based on a naturally-occurring corn earworm virus isolate that increases sterility in infected insects, aimed at controlling corn earworm in agricultural crops. The company holds a patent on the isolate and has submitted an EPA registration application ahead of commercialization.
2 investors
Level Nine develops a new class of catalysts ("nanozymes") that combine the precision of enzymes with the robustness of traditional catalysts to convert biobased feedstocks and waste streams into renewable chemical building blocks. It uses a machine-learning-driven catalyst discovery platform to produce drop-in replacements for petrochemicals in industrial-scale biobased chemistry.
2 investors
Lever Bio develops immunotherapy drug candidates in immuno-oncology, partnering with top researchers and academic institutions to translate discoveries into cancer immunotherapies. The company is focused on in-licensing and advancing promising programs from discovery through preclinical and clinical development stages.
2 investors